Market Closed -
Euronext Bruxelles
16:35:24 15/07/2024 BST
5-day change
1st Jan Change
426.5
EUR
-1.11%
+6.33%
+24.16%
Argenx : BlackRock Inc. - argenx SE - Breda
January 18, 2023 at 08:20 pm
BlackRock Inc. - argenx SE - Breda
BlackRock Inc. - argenx SE - Breda
Below you will find information from the register substantial holdings and gross short positions. The information has been provided by the organisation.
Date of transaction 17 jan 2023
Person obliged to notify BlackRock Inc.
Issuing institution argenx SE
Registration Chamber of Commerce 24435214
Place of residence Breda
Previous result
Next result
Distribution in numbers
Type of share
Number of shares
Number of voting rights
Capital interest
Voting rights
Manner of disposal
Settlement
Type of share Gewoon aandeel
Number of shares 62.490,00
Number of voting rights 67.831,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement Fysieke levering
Type of share Gewoon aandeel
Number of shares 1.977.403,00
Number of voting rights 2.424.723,00
Capital interest Reëel
Voting rights Reëel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement
Type of share Certificaat van aandeel
Number of shares 718.611,00
Number of voting rights 801.459,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(Blackrock, Inc.)
Settlement
Type of share Contract for difference
Number of shares 1.436,00
Number of voting rights 1.987,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement In contanten
Distribution in percentages
Type
Total holding
Directly real
Directly potential
Indirectly real
Indirectly potential
Type Kapitaalbelang
Total holding 4,98 %
Directly real 0,00 %
Directly potential 0,00 %
Indirectly real 3,57 %
Indirectly potential 1,41 %
Type Stemrecht
Total holding 5,95 %
Directly real 0,00 %
Directly potential 0,00 %
Indirectly real 4,38 %
Indirectly potential 1,57 %
Date last update: 18 January 2023
Disclaimer
arGEN-X SE published this content on 17 January 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 18 January 2023 20:19:00 UTC .
European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading
07-12
MT
Evercore ISI Raises Price Target on argenx to $533 From $478, Maintains Outperform Rating
07-12
MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
07-09
MT
Lexeo Therapeutics, Inc. Appoints Tim Van Hauwermeiren to Its Board of Directors
07-08
CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
07-02
MT
HC Wainwright Raises Argenx's Price Target to $490 From $448, Maintains Buy Rating
06-26
MT
Truist Securities Raises Argenx's Price Target to $480 From $440, Buy Rating Maintained
06-24
MT
Scotiabank Raises Argenx's Price Target to $416 From $408, Sector Perform Rating Maintained
06-24
MT
Goldman Sachs Raises Argenx's Price Target to $506 From $484, Buy Rating Maintained
06-24
MT
Citigroup Raises Argenx's Price Target to $512 From $463, Buy Rating Maintained
06-24
MT
European shares start the week higher on autos, banks
06-24
RE
Argenx Shares Rise Following Vyvgart Hytrulo Approval
06-24
MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
06-24
MT
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...
06-24
BofA Securities Raises Argenx Price Target to $607 From $535, Maintains Buy Rating
06-24
MT
Stifel Raises Argenx Price Target to $500 From $485, Maintains Buy Rating
06-24
MT
Sector Update: Health Care Stocks Advance Premarket Monday
06-24
MT
Piper Sandler Adjusts argenx Price Target to $535 From $522, Maintains Overweight Rating
06-24
MT
Wells Fargo Adjusts argenx Price Target to $542 From $478, Maintains Overweight Rating
06-24
MT
Evercore ISI Raises Price Target on argenx to $478 From $437, Keeps Outperform Rating
06-24
MT
Argenx Says FDA Approved Vyvgart Hytrulo for Treatment of Neuromuscular Disorder
06-24
MT
European shares start week on bright footing on autos, banks' boost
06-24
RE
Europe opens hesitant as metal prices fall
06-24
RE
European shares open flat as falling mining stocks curb gains
06-24
RE
Argenx Secures US FDA Approval for Chronic Inflammatory Demyelinating Polyneuropathy Treatment
06-24
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
More about the company
Last Close Price
426.5
EUR
Average target price
459.4
EUR
Spread / Average Target
+7.71%
Consensus
1st Jan change
Capi.
+24.16% 27.95B +20.63% 126B -20.17% 20.5B -16.06% 17.12B -18.07% 16.1B -47.70% 14.97B +11.92% 14.84B +58.32% 14.38B +149.98% 12.37B -10.27% 9.91B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1